Physiologically relevant curcuminoids inhibit angiogenesis via VEGFR2 in human aortic endothelial cells

Open data API in a single place

Provided by Zenodo

Get early access to Physiologically relevant curcuminoids inhibit angiogenesis via VEGFR2 in human aortic endothelial cells API!

Let us know and we will figure it out for you.

Dataset information

Country of origin
Updated
2024.07.15 00:00
Created
2022.01.01
Available languages
English
Keywords
Angiogenesis, Migration, Tubulogenesis, In Silico, Cell metabolism, Polyphenols, VEGFR2, VEGF
Quality scoring

Dataset description

Angiogenesis is a complex process encompassing endothelial cell proliferation, migration, and tube formation. While numerous studies describe that curcumin exerts antitumor properties (e.g., targeting angiogenesis), information regarding other dietary curcuminoids such as demethoxycurcumin (DMC) and bisdemethoxycurcumin (BisDMC) is scant. In this study, we evaluated the antiangiogenic activities of these three curcuminoids at physiological concentrations (0.1–5 μM) on endothelial cell migration and tubulogenesis and the underlying associated mechanisms on human aortic endothelial cells (HAECs). Results showed that the individual compounds and a representative mixture inhibited the tubulogenic and migration capacity of endothelial cells dose-dependently, while sparing cell viability. Notably, DMC and BisDMC at 0.1 and 1 μM showed higher capacity than curcumin inhibiting tubulogenesis. These compounds also reduced phosphorylation of the VEGFR2 and the downstream ERK and Akt pathways in VEGF165-stimulated cells. In silico analysis showed that curcuminoids could bind the VEGFR2 antagonizing the VEGF-mediated angiogenesis. These findings suggest that physiologically concentrations of curcuminoids might counteract pro-angiogenic stimuli relevant to tumorigenic processes.
European data infrastructure with broad catalog discovery, free evaluation access and production-grade API options.
190K+
indexed dataset pages
32
countries and EU institutions
2019
API-first since
Free API quota
for evaluation and prototypes
SLA
history and push on production APIs
FAQ

Questions before production use

Practical answers on evaluation, licensing, freshness, versioning and support.

api.store is built and operated by Apitalks s.r.o. Company details and a direct contact path are linked in the footer for vendor checks and procurement review.
Yes. Selected APIs include a free API quota, so your team can validate coverage, freshness, response shape and workflow fit before asking for a production plan.
Often yes, but usage rights depend on the source license and dataset. We surface source, license and update metadata where available, and can help review terms before a production integration.
Maintained APIs include update metadata where available. For production integrations, we can add history, monitoring and push updates so changes are easier to detect and act on.
Production APIs can add SLA, stable identifiers, versioning support, history, push updates and direct support around the data your product or AI workflow depends on.

Didn't find the API you need?

Let us know and we will figure it out for you.

European data discovery with free evaluation access and production-grade API options.

Copyright © 2026. Made by Apitalks